Remegen Co. Ltd. reported that telitacicept (RC-18) achieved the primary endpoint in a Phase III trial for primary Sjögren's syndrome, an autoimmune disease causing dry eyes and mouth. The company plans to submit a biologic license application (BLA) to China’s National Medical Products Administration based on these data. This breakthrough offers a new therapeutic avenue for patients with this challenging autoimmune condition and reflects Remegen’s growing presence in immunology therapeutics.